Physicochemical Properties
| Molecular Formula | C24H38O3 |
| Molecular Weight | 374.55672 |
| Exact Mass | 374.282 |
| CAS # | 56495-82-0 |
| PubChem CID | 5318483 |
| Appearance | Typically exists as solid at room temperature |
| Density | 0.97g/cm3 |
| Boiling Point | 483.4ºC at 760mmHg |
| Flash Point | 205.1ºC |
| Index of Refraction | 1.498 |
| LogP | 6.632 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 16 |
| Heavy Atom Count | 27 |
| Complexity | 526 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | CCCCCCC=CCCCCCCCCCC1=CC(=O)C=C(C1=O)OC |
| InChi Key | YYCCUFKHCNSRIA-HJWRWDBZSA-N |
| InChi Code | InChI=1S/C24H38O3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-21-19-22(25)20-23(27-2)24(21)26/h8-9,19-20H,3-7,10-18H2,1-2H3/b9-8- |
| Chemical Name | 2-[(Z)-heptadec-10-enyl]-6-methoxycyclohexa-2,5-diene-1,4-dione |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | C6 neuroastroma cells are exposed to radiation cues when exposed to isisquinone (0–128 nM, 12-48 h) [2]. In Stowe C6 neuroastroma cells, irisquinone (4.2 nM, 48 h) amplifies radioactive cues [2]. |
| ln Vivo | Irisquinone (12.5 mg/kg, daily infusion) made the tumor wall thinner and the abdomen area increased in the Irisquinone + radiation group in the rabbit VX2 lung transplant tumor model [1]. |
| Cell Assay |
Cell Viability Assay[2] Cell Types: C6 Rat Glioma Cells Tested Concentrations: 0, 4, 8, 16, 32, 64, 128 nM Incubation Duration: 12, 24, 48 hrs (hours) Experimental Results: Time-dependent and dose-dependent Sexually inhibit cell viability. |
| Animal Protocol |
Animal/Disease Models: Rabbits bearing VX2 lung transplant tumors [1] Doses: 12.5 mg/kg Route of Administration: daily infusion from 3 days before irradiation to the end of irradiation. Experimental Results: There was no significant difference in tumor growth between the radiotherapy group and the irisquinone + radiotherapy group. The tumor wall in the irisquinone + radiotherapy group was thinner and the necrosis area was larger. |
| References |
[1]. Dynamic observation of the radiosensitive effect of irisquinone on rabbit VX2 lung transplant tumors by using fluorine-18-deoxyglucose positron emission tomography/computed tomography. Nucl Med Commun. 2013 Mar;34(3):220-8. [2]. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT. Nucl Med Commun. 2016 Jul;37(7):705-14. [3]. The effect of Irisquinone on the glutathione system and MRP expression of cisplatin-resistant human lung adenocarcinoma cell line (A DDP549). Chin J Cancer Res 13, 171–175 (2001). |
| Additional Infomation | Irisquinone has been reported in Iris missouriensis, Iris sibirica, and other organisms with data available. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6698 mL | 13.3490 mL | 26.6980 mL | |
| 5 mM | 0.5340 mL | 2.6698 mL | 5.3396 mL | |
| 10 mM | 0.2670 mL | 1.3349 mL | 2.6698 mL |